Wall Street Zen upgraded shares of Allovir (NASDAQ:KLRS - Free Report) from a sell rating to a hold rating in a report issued on Sunday morning.
Allovir Stock Up 3.4%
Shares of NASDAQ:KLRS traded up $0.10 during midday trading on Friday, reaching $3.00. 11,867 shares of the company's stock traded hands, compared to its average volume of 37,561. Allovir has a one year low of $2.64 and a one year high of $24.15.
About Allovir
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Featured Articles
Before you consider Allovir, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allovir wasn't on the list.
While Allovir currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
